Top

Archives of Gynecology and Obstetrics

Published in:

01-03-2014 | Maternal-Fetal Medicine

eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women

Authors: T. Groten, E. Schleussner, T. Lehmann, F. Reister, B. Holzer, K. A. Danso, R. Zeillinger

Published in: Archives of Gynecology and Obstetrics | Issue 3/2014

Abstract

Purpose

The aim of this study was to evaluate possible associations of genetic polymorphisms predisposing to cardiovascular disease with the development and/or the severity of preeclampsia.

Methods

A two hospital-based prospective case–control study was performed in Germany and Ghana. 470 blood samples of 250 Caucasian and 220 black African have been genotyped by pyrosequencing and fragment length analysis. We evaluated the distribution of the epoxide hydrolase 1 (EPHX1) polymorphism on exon 3, the endothelial nitric oxide synthase (eNOS) polymorphisms on exon 7 and on intron 4, the angiotensinogen polymorphism on exon 2 and the estrogen receptor 1 polymorphism in intron 1.

Results

74 Caucasian and 84 African were classified as preeclampsia with 27 Caucasian developing a hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome and 17 African women experiencing eclampsia. Multivariate logistic regression analysis adjusting for ethnicity, age and parity revealed for carriers of eNOSI4 VNTR4a a 1.7-fold increased (95 % CI 1.10–2.711, p = 0.016) risk to develop preeclampsia and a 3.6-fold increase for carriers of the EPHX1 113Tyr (95 % CI 1.366–8.750, p = 0.009) to develop severest preeclampsia.

Conclusion

Our finding of eNOSI4 polymorphism predisposing to preeclampsia independently of ethnicity, age and parity supports the concept of NO being involved in the endothelial disorder preeclampsia. Since EPHX1 is highly expressed in the liver, can interact with various signaling pathways and is involved in central nervous system disorders, the association of EPHX1 polymorphism with the HELLP syndrome and eclampsia may hint to EPHX being a further key player in the pathogenesis of preeclampsia.

Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R (2010) Pre-eclampsia. Lancet 376(9741):631–644. doi:10.1016/S0140-6736(10)60279-6 PubMedCrossRef

Haram K, Svendsen E, Abildgaard U (2009) The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth 9:8. doi:10.1186/1471-2393-9-8 PubMedCentralPubMedCrossRef

Hladunewich MA, Myers BD, Derby GC, Blouch KL, Druzin ML, Deen WM, Naimark DM, Lafayette RA (2008) Course of preeclamptic glomerular injury after delivery. Am J Physiol Ren Physiol 294(3):F614–F620. doi:10.1152/ajprenal.00470.2007 CrossRef

Bellamy L, Casas JP, Hingorani AD, Williams DJ (2007) Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335(7627):974. doi:10.1136/bmj.39335.385301.BE PubMedCrossRef

McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ (2008) Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 156(5):918–930. doi:10.1016/j.ahj.2008.06.042 PubMedCrossRef

Bushnell C, Chireau M (2011) Preeclampsia and stroke: risks during and after pregnancy. Stroke Res Treat 2011:858134. doi:10.4061/2011/858134 PubMedCentralPubMed

Roberts JM, Hubel CA (2009) The two stage model of preeclampsia: variations on the theme. Placenta 30(Suppl A):S32–S37. doi:10.1016/j.placenta.2008.11.009 PubMedCentralPubMedCrossRef

Huppertz B (2008) Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 51(4):970–975. doi:10.1161/HYPERTENSIONAHA.107.107607 PubMedCrossRef

Mutze S, Rudnik-Schoneborn S, Zerres K, Rath W (2008) Genes and the preeclampsia syndrome. J Perinat Med 36(1):38–58. doi:10.1515/JPM.2008.004 PubMedCrossRef

10.

Schroeder BM (2002) ACOG practice bulletin on diagnosing and managing preeclampsia and eclampsia. American college of obstetricians and gynecologists. Am Fam Physician 66(2):330–331PubMed

11.

Tempfer CB, Dorman K, Deter RL, O’Brien WE, Gregg AR (2001) An endothelial nitric oxide synthase gene polymorphism is associated with preeclampsia. Hypertens Pregnancy 20(1):107–118. doi:10.1081/PRG-100104177 PubMed

12.

Tempfer CB, Jirecek S, Riener EK, Zeisler H, Denschlag D, Hefler L, Husslein PW (2004) Polymorphisms of thrombophilic and vasoactive genes and severe preeclampsia: a pilot study. J Soc Gynecol Investig 11(4):227–231. doi:10.1016/j.jsgi.2003.12.002 PubMedCrossRef

13.

Medica I, Kastrin A, Peterlin B (2007) Genetic polymorphisms in vasoactive genes and preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 131(2):115–126. doi:10.1016/j.ejogrb.2006.10.005 PubMedCrossRef

14.

Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, Farrington PF, Ogasawara M, Suzumori K, Tomoda S et al (1993) A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet 4(1):59–61. doi:10.1038/ng0593-59 PubMedCrossRef

15.

Motawi T, Shaker O, Taha M, Sedrak H, Nabil M (2011) Endothelial nitric oxide synthase and angiotensinogen gene polymorphism in coronary artery diseases in Egypt. Angiology 62(2):191–197. doi:10.1177/0003319710373094 PubMedCrossRef

16.

Morgan T, Ward K (1999) New insights into the genetics of preeclampsia. Semin Perinatol 23(1):14–23PubMedCrossRef

17.

Groten T, Pierce AA, Huen AC, Schnaper HW (2005) 17 beta-estradiol transiently disrupts adherens junctions in endothelial cells. FASEB J 19(10):1368–1370. doi:10.1096/fj.04-2558fje PubMed

18.

Ellis JA, Infantino T, Harrap SB (2004) Sex-dependent association of blood pressure with oestrogen receptor genes ERalpha and ERbeta. J Hypertens 22(6):1127–1131 (pii: 00004872-200406000-00013)PubMedCrossRef

19.

Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG (2004) Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 291(24):2969–2977. doi:10.1001/jama.291.24.2969 PubMedCrossRef

20.

Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER (2002) Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 105(16):1879–1882PubMedCrossRef

21.

Molvarec A, Ver A, Fekete A, Rosta K, Derzbach L, Derzsy Z, Karadi I, Rigo J Jr (2007) Association between estrogen receptor alpha (ESR1) gene polymorphisms and severe preeclampsia. Hypertens Res 30(3):205–211. doi:10.1291/hypres.30.205 PubMedCrossRef

22.

Zhang J, Bai H, Liu X, Fan P, Liu R, Huang Y, Wang X, He G, Liu Y, Liu B (2009) Genotype distribution of estrogen receptor alpha polymorphisms in pregnant women from healthy and preeclampsia populations and its relation to blood pressure levels. Clin Chem Lab Med 47(4):391–397. doi:10.1515/CCLM.2009.096 PubMedCrossRef

23.

Rush JW, Denniss SG, Graham DA (2005) Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol 30(4):442–474PubMedCrossRef

24.

Fisher AB, Chien S, Barakat AI, Nerem RM (2001) Endothelial cellular response to altered shear stress. Am J Physiol Lung Cell Mol Physiol 281(3):L529–L533PubMed

25.

Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A (2004) Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci USA 101(37):13683–13688. doi:10.1073/pnas.0402927101 PubMedCrossRef

26.

Morris NH, Eaton BM, Dekker G (1996) Nitric oxide, the endothelium, pregnancy and pre-eclampsia. Br J Obstet Gynaecol 103(1):4–15PubMedCrossRef

27.

Nakayama M, Yoshimura M, Sakamoto T, Abe K, Yamamuro M, Shono M, Suzuki S, Nishijima T, Miyamoto Y, Saito Y, Nakao K, Yasue H, Ogawa H (2006) A -786T > C polymorphism in the endothelial nitric oxide synthase gene reduces serum nitrite/nitrate levels from the heart due to an intracoronary injection of acetylcholine. Pharmacogenet Genomics 16(5):339–345. doi:10.1097/01.fpc.0000199499.08725.d5 PubMedCrossRef

28.

Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD (2006) Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol 164(10):921–935. doi:10.1093/aje/kwj302 PubMedCrossRef

29.

Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P (2002) The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 20(10):2023–2027PubMedCrossRef

30.

Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, Haydock S, Hopper RV, Stephens NG, O’Shaughnessy KM, Brown MJ (1999) A common variant of the endothelial nitric oxide synthase (Glu298– > Asp) is a major risk factor for coronary artery disease in the UK. Circulation 100(14):1515–1520PubMedCrossRef

31.

Kim IJ, Bae J, Lim SW, Cha DH, Cho HJ, Kim S, Yang DH, Hwang SG, Oh D, Kim NK (2007) Influence of endothelial nitric oxide synthase gene polymorphisms (-786T > C, 4a4b, 894G > T) in Korean patients with coronary artery disease. Thromb Res 119(5):579–585. doi:10.1016/j.thromres.2006.06.005 PubMedCrossRef

32.

Tang W, Yang Y, Wang B, Xiao C (2008) Association between a G894T polymorphism of eNOS gene and essential hypertension in Hani and Yi minority groups of China. Arch Med Res 39(2):222–225. doi:10.1016/j.arcmed.2007.08.002 PubMedCrossRef

33.

Hakli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Endothelial nitric oxide synthase polymorphism in preeclampsia. J Soc Gynecol Investig 10(3):154–157 (pii:S1071557603000030)PubMedCrossRef

34.

Serrano NC, Casas JP, Diaz LA, Paez C, Mesa CM, Cifuentes R, Monterrosa A, Bautista A, Hawe E, Hingorani AD, Vallance P, Lopez-Jaramillo P (2004) Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study. Hypertension 44(5):702–707. doi:10.1161/01.HYP.0000143483.66701.ec PubMedCrossRef

35.

Tanus-Santos JE, Desai M, Flockhart DA (2001) Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11(8):719–725PubMedCrossRef

36.

Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T, Igari J (1998) Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 245(1):190–193. doi:10.1006/bbrc.1998.8267 PubMedCrossRef

37.

Sandrim VC, Palei AC, Sertorio JT, Cavalli RC, Duarte G, Tanus-Santos JE (2010) Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia. Mol Hum Reprod 16(7):506–510. doi:10.1093/molehr/gaq030 PubMedCrossRef

38.

Wang XL, Wang J (2000) Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol Genet Metab 70(4):241–251. doi:10.1006/mgme.2000.3033 PubMedCrossRef

39.

Howard TD, Giles WH, Xu J, Wozniak MA, Malarcher AM, Lange LA, Macko RF, Basehore MJ, Meyers DA, Cole JW, Kittner SJ (2005) Promoter polymorphisms in the nitric oxide synthase 3 gene are associated with ischemic stroke susceptibility in young black women. Stroke 36(9):1848–1851. doi:10.1161/01.STR.0000177978.97428.53 PubMedCentralPubMedCrossRef

40.

Sigusch HH, Surber R, Lehmann MH, Surber S, Weber J, Henke A, Reinhardt D, Hoffmann A, Figulla HR (2000) Lack of association between 27-bp repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene and the risk of coronary artery disease. Scand J Clin Lab Invest 60(3):229–235PubMedCrossRef

41.

Aggarwal PK, Jain V, Jha V (2010) Endothelial nitric oxide synthase, angiotensin-converting enzyme and angiotensinogen gene polymorphisms in hypertensive disorders of pregnancy. Hypertens Res 33(5):473–477. doi:10.1038/hr.2010.23 PubMedCrossRef

42.

Decker M, Arand M, Cronin A (2009) Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch Toxicol 83(4):297–318. doi:10.1007/s00204-009-0416-0 PubMedCrossRef

43.

Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gosele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, Gross V, Hummel O, Maatz H, Patone G, Saar K, Vingron M, Weldon SM, Lindpaintner K, Hammock BD, Rohde K, Dietz R, Cook SA, Schunck WH, Luft FC, Hubner N (2008) Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40(5):529–537. doi:10.1038/ng.129 PubMedCrossRef

44.

Fandrich F, Degiuli B, Vogel-Bindel U, Arand M, Oesch F (1995) Induction of rat liver microsomal epoxide hydrolase by its endogenous substrate 16 alpha, 17 alpha-epoxyestra-1,3,5-trien-3-ol. Xenobiotica 25(3):239–244. doi:10.3109/00498259509061848 PubMedCrossRef

45.

Liu M, Sun A, Shin EJ, Liu X, Kim SG, Runyons CR, Markesbery W, Kim HC, Bing G (2006) Expression of microsomal epoxide hydrolase is elevated in Alzheimer’s hippocampus and induced by exogenous beta-amyloid and trimethyl-tin. Eur J Neurosci 23(8):2027–2034. doi:10.1111/j.1460-9568.2006.04724.x PubMedCrossRef

46.

Farin FM, Janssen P, Quigley S, Abbott D, Hassett C, Smith-Weller T, Franklin GM, Swanson PD, Longstreth WT Jr, Omiecinski CJ, Checkoway H (2001) Genetic polymorphisms of microsomal and soluble epoxide hydrolase and the risk of Parkinson’s disease. Pharmacogenetics 11(8):703–708PubMedCrossRef

47.

Robbins DK, Wedlund PJ, Elsberg S, Oesch F, Thomas H (1992) Interaction of valproic acid and some analogues with microsomal epoxide hydrolase. Biochem Pharmacol 43(4):775–783PubMedCrossRef

48.

Omiecinski CJ, Hassett C, Hosagrahara V (2000) Epoxide hydrolase-polymorphism and role in toxicology. Toxicol Lett 112–113:365–370 (pii: S0378427499002350)PubMedCrossRef

49.

Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ (1997) Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys 337(2):275–283. doi:10.1006/abbi.1996.9794 PubMedCrossRef

50.

Rosenberger A, Illig T, Korb K, Klopp N, Zietemann V, Wolke G, Meese E, Sybrecht G, Kronenberg F, Cebulla M, Degen M, Drings P, Groschel A, Konietzko N, Kreymborg KG, Haussinger K, Hoffken G, Jilge B, Ko YD, Morr H, Schmidt C, Schmidt EW, Tauscher D, Bickeboller H, Wichmann HE (2008) Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. BMC Cancer 8:60. doi:10.1186/1471-2407-8-60 PubMedCentralPubMedCrossRef

51.

Zusterzeel PL, Peters WH, Visser W, Hermsen KJ, Roelofs HM, Steegers EA (2001) A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia. J Med Genet 38(4):234–237PubMedCrossRef

52.

Pinarbasi E, Percin FE, Yilmaz M, Akgun E, Cetin M, Cetin A (2007) Association of microsomal epoxide hydrolase gene polymorphism and pre-eclampsia in Turkish women. J Obstet Gynaecol Res 33(1):32–37. doi:10.1111/j.1447-0756.2007.00473.x PubMedCrossRef

53.

Laasanen J, Romppanen EL, Hiltunen M, Helisalmi S, Mannermaa A, Punnonen K, Heinonen S (2002) Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are jointly associated with preeclampsia. Eur J Hum Genet 10(9):569–573. doi:10.1038/sj.ejhg.5200849 PubMedCrossRef

54.

Gebhardt GS, Peters WH, Hillermann R, Odendaal HJ, Carelse-Tofa K, Raijmakers MT, Steegers EA (2004) Maternal and fetal single nucleotide polymorphisms in the epoxide hydrolase and gluthatione S-transferase P1 genes are not associated with pre-eclampsia in the Coloured population of the Western Cape. South Africa. J Obstet Gynaecol 24(8):866–872. doi:10.1080/01443610400018841 CrossRef

55.

Yousif MH, Benter IF (2010) Role of 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of vascular function in a model of hypertension and endothelial dysfunction. Pharmacology 86(3):149–156. doi:10.1159/000317521 PubMedCrossRef

56.

Zhang LN, Vincelette J, Chen D, Gless RD, Anandan SK, Rubanyi GM, Webb HK, MacIntyre DE, Wang YX (2011) Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension. Eur J Pharmacol 654(1):68–74. doi:10.1016/j.ejphar.2010.12.016 PubMedCrossRef

Title: eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women
Authors: T. Groten
E. Schleussner
T. Lehmann
F. Reister
B. Holzer
K. A. Danso
R. Zeillinger
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2014
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-013-2991-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2014

Anesthetic considerations for high order cesarean sections: a prospective cohort study

Letter to the editor referring to the manuscript entitled: “Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine” reported by Sotiriadis et al. (Arch Gynecol Obstet. 2012 Jun;285(6):1719–24)

Cervical cytology with a diagnosis of atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a follow-up study with corresponding histology and significance of predicting dysplasia by human papillomavirus (HPV) DNA testing

Computed tomography adnexal mass score to estimate risk for ovarian cancer

Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial

Comparing the efficacy of intrauterine lidocaine and paracervical block in decreasing the pain associated with endometrial biopsy: a randomised trial